UNSPSC 51111773: Vinzolidine

This classification denotes a vinca-site binding agent with the molecular formula C48H58ClN5O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 533U947V6Q, chemically known as 2h-3,7-methanoazacycloundecino(5,4-b)indole-9-carboxylic acid, 9-((2beta,3beta,4beta,5alpha,12beta,19alpha)-4-(acetyloxy)-3-(2-chloroethyl)-6,7-didehydro-16-methoxy-1-methyl-2,4-dioxospiro(aspidospermidine-3,5-oxazolidin)-15-yl)-5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-, methyl ester, (3r-(3r*,5s*,7r*,9s*))- but generally known as vinzolidine, which bears US NIH Compound Identifier 49966.

UNSPSC 51111773 Vinzolidine, a Commodity code, nominally covers a specific pharmaceutical product, but recent state and local solicitations tagged with this code show minimal direct purchasing activity for vinzolidine itself. Instead, the code appears in procurement records spanning broader pharmaceutical and medical supply acquisitions, including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and pharmacy benefit program initiatives. The issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and cooperative purchasing alliances representing multiple state and local jurisdictions. Work solicited under the code encompasses procurement of finished pharmaceutical products, medical consumables, and pharmacy benefit program implementation services rather than active pharmaceutical ingredients or manufacturing inputs.

Recent opportunities show activity across Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The City of Tampa released ITB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with a $700,000 estimated contract value and a 5 percent SLBE bid discount program, response due March 13, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements. The code shows scattered activity rather than concentrated demand, with no single jurisdiction appearing as a repeat buyer across the recent opportunities documented.